TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34184251

Group type: EXPERIMENTAL
Intervention: Interventions to reduce sedentary behaviour (including physical activity interventions, multicomponent lifestyle interventions, and interventions to interrupt sedentary behaviour)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Interventions to reduce sedentary behaviour
Number of subjects: 753
Study: 34184326

Group type: EXPERIMENTAL
Intervention: Elevated dd-cfDNA (≥1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dd-cfDNA variability (≥.34%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Samples from patients with concurrent de novo HLA DSAs
Number of subjects: 0
Study: 34184441

Group type: EXPERIMENTAL
Intervention: Fimasartan-based antihypertensive therapy
Number of subjects: 1035
Study: 34184659

Group type: EXPERIMENTAL
Intervention: Overinvestment
Number of subjects: 1774

Group type: EXPERIMENTAL
Intervention: Job Demand Control Support and Effort-Reward Imbalance models
Number of subjects: 1774
Study: 34184935

Group type: EXPERIMENTAL
Intervention: Thoracic CT
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Extent of pneumonia at CT
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Clinical variables score
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Clinical variables score + extent of pneumonia and coronary calcium score at CT
Number of subjects: 10735
Study: 34185002

Group type: EXPERIMENTAL
Intervention: Personalized dietary advice
Number of subjects: 37
Study: 34185020

Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence program (IMAP) with regular motivational interviewing sessions and delivery of PKIs in electronic monitors
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence program (IMAP)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: PKI pharmacokinetics
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: PKI dosage adaptation
Number of subjects: 262
Study: 34185022

Group type: EXPERIMENTAL
Intervention: Interactive life-simulation game
Number of subjects: 300

Group type: COMPARATOR
Intervention: App-based HIV educational materials
Number of subjects: 300
Study: 34185084

Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard-care medications (triptans or over-the-counter medications)
Number of subjects: 35
Study: 34185220

Group type: EXPERIMENTAL
Intervention: CHD survivors
Number of subjects: 744

Group type: COMPARATOR
Intervention: General population
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: CHD survivors with severe functional limitations
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: CHD care in the Midwest
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Illness perception dimensions (Concern and Emotional Response)
Number of subjects: 744
Study: 34185611

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34185708

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 0
Study: 34185827

Group type: EXPERIMENTAL
Intervention: HFRS (Hospital Frailty Risk Score)
Number of subjects: 1042234
Study: 34185838

Group type: EXPERIMENTAL
Intervention: ART initiated <48 hours after birth
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ART initiated <14 days after birth
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ART initiated >14 days after birth
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No antenatal maternal ART
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 63
Study: 34185953

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9 μg/day for week 1, 28 μg/day for weeks 2-4, followed by 2 weeks of no treatment; 28 μg/day in subsequent cycles)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 45
Study: 34186052

Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope by expert endoscopists
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope by less-expert endoscopists
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Procedures of high complexity (grades 3-4)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 200
Study: 34186262

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir (SOF/LED)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Total bilirubin ≥1.93 mg/dL
Number of subjects: 26
Study: 34187182

Group type: EXPERIMENTAL
Intervention: Preprocedural plasma levels of MRproANP (midregional N-terminal pro-atrial natriuretic peptide)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Preprocedural plasma levels of sST2 (soluble suppression of tumorigenicity 2)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation
Number of subjects: 106
Study: 34187187

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 93
Study: 34187401

Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg intravenous on days 1, 8, 15 for 6 cycles of 28 days) and Rituximab (375 mg/m2)
Number of subjects: 0
Study: 34187516

Group type: EXPERIMENTAL
Intervention: Dercum's disease (DD)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Roch-Leri mesosomatic lipomatosis (LMS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 46

Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 46
Study: 34187614

Group type: EXPERIMENTAL
Intervention: Pre-pandemic lifetime mental disorders
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Current mental disorders
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Generalised anxiety disorder
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Panic attacks
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Alcohol/substance use disorder
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Pandemic-related adverse events-experiences
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Having loved ones infected with COVID-19
Number of subjects: 3500
Study: 34187698

Group type: EXPERIMENTAL
Intervention: Management of malnutrition (MN)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Management of oropharyngeal dysphagia (OD)
Number of subjects: 205
Study: 34187739

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs) against immune checkpoints (ICIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Druggable strategies modulating PD-L1 expression
Number of subjects: 0
Study: 34187821

Group type: EXPERIMENTAL
Intervention: Clinical decision support system for FQ PPA integrated into EHRs
Number of subjects: 12
Study: 34187831

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) measured by modified Rankin Scale scores
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Self-Rated Health (SRH)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Further measures of ADL, functional health, physical activity, falls and fatigue
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Views on ageing, social support, resilience-related concepts, affect, frailty, illness perceptions and loneliness
Number of subjects: 300
Study: 34187841

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (n = 28)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normoglycemia (n = 48)
Number of subjects: 76
Study: 34187851

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 inhibition (2 cycles)
Number of subjects: 20
Study: 34187867

Group type: EXPERIMENTAL
Intervention: NfL plasma concentrations in AD patients
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: p-tau181 plasma concentrations in AD patients
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Baseline concentrations of p-tau181 and NfL
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Rate of change of NfL
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 865
Study: 34187871

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with concurrent intravenous (IV) alteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) only
Number of subjects: 0
Study: 34187993

Group type: EXPERIMENTAL
Intervention: HEAR score <2
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Two-step HEART strategy
Number of subjects: 1402
Study: 34188166

Group type: EXPERIMENTAL
Intervention: Serum PTX3 above 4.34 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum CA19-9 and CEA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stromal modulation by ATRA
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCALOP clinical trial (chemo-radiotherapy without stromal targeting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STARPAC clinical trial (NCT03307148)
Number of subjects: 0
Study: 34188440

Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling
Number of subjects: 10
Study: 34188580

Group type: EXPERIMENTAL
Intervention: pdVWF/FVIII (VONCENTO)
Number of subjects: 35
Study: 34189178

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg) with loperamide
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg) with loperamide
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Rifaximin (1650 mg) with loperamide
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (pre-antibiotic treatment)
Number of subjects: 119
Study: 34189463

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg every 2 weeks for 12 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 2
Study: 34190375

Group type: EXPERIMENTAL
Intervention: Sunitinib (SUN) plus Evofosfamide (EVO) 340 mg/m
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sunitinib (SUN) plus Evofosfamide (EVO)
Number of subjects: 17
Study: 34190592

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm activated in patients
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Clinical actions taken in response to HeartLogic alerts
Number of subjects: 366

Group type: COMPARATOR
Intervention: Extra in-office visits for managing HeartLogic alerts
Number of subjects: 366
Study: 34190999

Group type: EXPERIMENTAL
Intervention: Targeted messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no targeted messaging)
Number of subjects: 0
Study: 34191021

Group type: EXPERIMENTAL
Intervention: Plain kale
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Kale with 1.2% added sugar
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Kale with 1.8% added sugar
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Kale with 0.2% added salt
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Older infants (≥18 mo)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Breastfeeding history
Number of subjects: 106
Study: 34191195

Group type: EXPERIMENTAL
Intervention: FLT-PET/DW-MRI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FLT-PET
Number of subjects: 12

Group type: COMPARATOR
Intervention: FDG-PET/CT
Number of subjects: 12
Study: 34191201

Group type: EXPERIMENTAL
Intervention: Taxane- or platinum-based chemotherapy
Number of subjects: 116
Study: 34191621

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) at 225 mg twice daily
Number of subjects: 138
Study: 34192154

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody testing using chemiluminescence assays (chemiluminescence immunoassay and electrochemiluminescence)
Number of subjects: 318

Group type: COMPARATOR
Intervention: ELISA and POC testing
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Antiviral antibody titres
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Testing methods
Number of subjects: 318
Study: 34192239

Group type: EXPERIMENTAL
Intervention: Chatbot users for breast cancer, asthma, depression, and migraine
Number of subjects: 1771
Study: 34192953

Group type: EXPERIMENTAL
Intervention: Cardiac screening including ECG, echocardiography, and 24-hour Holter monitoring
Number of subjects: 145
Study: 34192989

Group type: EXPERIMENTAL
Intervention: LBSA0103 hyaluronic acid injection
Number of subjects: 1949
Study: 34193084

Group type: EXPERIMENTAL
Intervention: Prognostic prediction model for falls rate
Number of subjects: 198
Study: 34193096

Group type: EXPERIMENTAL
Intervention: Community-based intervention consisting of a 20-25 min oral presentation in Urdu and Somali on cervical cancer and screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women from Pakistan and Somalia residing in Oslo).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based intervention (I).
Number of subjects: 0
Study: 34193138

Group type: EXPERIMENTAL
Intervention: Routinised syphilis testing alongside regular viral load bloodwork
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Routinised syphilis testing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Opting out of testing based on self-assessment of syphilis risk
Number of subjects: 21
Study: 34193140

Group type: EXPERIMENTAL
Intervention: Machine learning model predicting presence of immune-related adverse events (irAEs) using ePRO data.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Machine learning model predicting onset of immune-related adverse events (irAEs) using ePRO data.
Number of subjects: 34
Study: 34193171

Group type: EXPERIMENTAL
Intervention: Image fusion system (n=5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 10
Study: 34193208

Group type: EXPERIMENTAL
Intervention: Monocyte distribution width (MDW)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: MDW combined with WBC
Number of subjects: 1517

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Procalcitonin (PCT)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Abnormal MDW
Number of subjects: 1517
Study: 34193214

Group type: EXPERIMENTAL
Intervention: Concordant 1 couples (70.3% agreed women were involved)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Discordant 2 couples (12.2% had women report uninvolvement but men report involvement)
Number of subjects: 961
Study: 34193433

Group type: EXPERIMENTAL
Intervention: Indoor environmental exposures
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Measures of indoor air quality constituents
Number of subjects: 240
Study: 34193488

Group type: EXPERIMENTAL
Intervention: Weight-related discussions initiated by healthcare professionals (HCPs)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Weight-related discussions initiated by people with obesity (PwO)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Perceptions of responsibility for weight loss
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Criteria for initiating weight management conversations
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Reasons for not discussing weight by HCPs
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Patient preferences for weight discussions
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Emotional responses of PwO after weight discussions
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Follow-up appointments after weight discussions
Number of subjects: 1500
Study: 34193595

Group type: EXPERIMENTAL
Intervention: Newer drugs targeting novel blood glucose-lowering pathways
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pharmacologic therapies (insulin, metformin, sulfonylureas)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatments targeting incretin action, islet transplantation, generation of functional beta cells from stem cells
Number of subjects: 0
Study: 34194387

Group type: EXPERIMENTAL
Intervention: Non-invasive assessment using retinal vessel analysis
Number of subjects: 0
Study: 34194396

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 34194586

Group type: EXPERIMENTAL
Intervention: Arousal predominant group
Number of subjects: 577

Group type: COMPARATOR
Intervention: Nonarousal predominant group
Number of subjects: 577
Study: 34194721

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) therapy for 12 months
Number of subjects: 37
Study: 34195237

Group type: EXPERIMENTAL
Intervention: Body-weight fluctuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34195252

Group type: EXPERIMENTAL
Intervention: Endobronchial administration of autologous bone marrow mesenchymal stromal cells (BM-MSCs)
Number of subjects: 13
Study: 34195402

Group type: EXPERIMENTAL
Intervention: Arteek-SP
Number of subjects: 179

Group type: COMPARATOR
Intervention: Septanest
Number of subjects: 179
Study: 34195471

Group type: EXPERIMENTAL
Intervention: Preoperative preparation with Lugol's Solution (LS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no preoperative preparation with LS)
Number of subjects: 270
Study: 34195486

Group type: EXPERIMENTAL
Intervention: Lattice SBRT
Number of subjects: 11
Study: 34195525

Group type: EXPERIMENTAL
Intervention: PRKAR1B p.R115K variant
Number of subjects: 457

Group type: COMPARATOR
Intervention: Wildtype PRKAR1B
Number of subjects: 457
Study: 34195575

Group type: EXPERIMENTAL
Intervention: 1% aqueous CHG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1% CHG plus emollient
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Emollient only
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (SOC: no antiseptic/emollient)
Number of subjects: 80
Study: 34195683

Group type: EXPERIMENTAL
Intervention: Proteomics analysis of sentinel lymph nodes (SLN) from individuals with endometrial cancer (EC)
Number of subjects: 0
Study: 34195794

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) and/or low-dose aspirin (ASA)
Number of subjects: 265

Group type: COMPARATOR
Intervention: No treatment (absence of LMWH/ASA)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: LMWH (with or without ASA)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: LMWH prophylaxis (alone or in association with ASA)
Number of subjects: 265
Study: 34195803

Group type: EXPERIMENTAL
Intervention: hs-cTnT-Elecsys
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: hs-cTnI-Architect
Number of subjects: 5887
Study: 34196037

Group type: EXPERIMENTAL
Intervention: Entospletinib in combination with obinutuzumab
Number of subjects: 17
Study: 34196165

Group type: EXPERIMENTAL
Intervention: Tafasitamab (12 mg/kg intravenously) plus Lenalidomide (25 mg orally)
Number of subjects: 80
Study: 34196381

Group type: EXPERIMENTAL
Intervention: TR3 technique
Number of subjects: 8
Study: 34196676

Group type: EXPERIMENTAL
Intervention: Betibeglogene autotemcel (beti-cel) gene therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 1
Study: 34196963

Group type: COMPARATOR
Intervention: Visual interventions
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Prism adaptation
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Body awareness interventions
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Non-invasive brain stimulation (NIBS)
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Mental function interventions
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Movement interventions
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 1951
Study: 34196991

Group type: EXPERIMENTAL
Intervention: Ultralow temperature cryoablation using near-critical nitrogen
Number of subjects: 30
Study: 34197151

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 34197184

Group type: EXPERIMENTAL
Intervention: High-altitude environment
Number of subjects: 0
Study: 34197212

Group type: EXPERIMENTAL
Intervention: Enzalutamide (N = 21)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Abiraterone (N = 27)
Number of subjects: 99
Study: 34197356

Group type: EXPERIMENTAL
Intervention: Gadopiclenol (0.1 mmol/kg)
Number of subjects: 40
Study: 34198246

Group type: EXPERIMENTAL
Intervention: MT+IVT
Number of subjects: 2895

Group type: COMPARATOR
Intervention: MT
Number of subjects: 2895
Study: 34198338

Group type: EXPERIMENTAL
Intervention: Early postoperative atrial fibrillation (POAF) detected in 27 patients (34%)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Late POAF episodes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Electrically induced AF in POAF patients
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Predictors of late POAF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Patients with early POAF, higher age, larger RA, or prolonged PR time
Number of subjects: 79
Study: 34199550

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-vegan diet
Number of subjects: 80
Study: 34199925

Group type: EXPERIMENTAL
Intervention: Bronchial allergen challenge in AA patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eosinophils from SNEA patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy subjects (HS)
Number of subjects: 38
Study: 34200102

Group type: EXPERIMENTAL
Intervention: Higher protein intake in TT-genotype carriers
Number of subjects: 810
Study: 34200140

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 100
Study: 34200805

Group type: EXPERIMENTAL
Intervention: Personalised exercise group programme + app with motivational messages
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Personalised exercise group programme + app with no motivational messages
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (app with no motivational messages)
Number of subjects: 172
Study: 34201045

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm for detecting and classifying choroidal neovascularization (CNV) on spectral-domain optical coherence tomography (SD-OCT) images.
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm for classifying CNV types on SD-OCT images.
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm for discriminating CNV types on baseline SD-OCT images.
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm for detecting CNV presence and subtypes on SD-OCT images.
Number of subjects: 1568
Study: 34201380

Group type: EXPERIMENTAL
Intervention: Targeted osmotic lysis
Number of subjects: 1